140 related articles for article (PubMed ID: 23116325)
1. Randomized controlled trial comparing highly purified (HP-hCG) and recombinant hCG (r-hCG) for triggering ovulation in ART.
Bellavia M; de Geyter C; Streuli I; Ibecheole V; Birkhäuser MH; Cometti BP; de Ziegler D
Gynecol Endocrinol; 2013 Feb; 29(2):93-7. PubMed ID: 23116325
[TBL] [Abstract][Full Text] [Related]
2. Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: a randomized controlled trial.
Kolibianakis EM; Venetis CA; Bosdou JK; Zepiridis L; Chatzimeletiou K; Makedos A; Masouridou S; Triantafillidis S; Mitsoli A; Tarlatzis BC
Hum Reprod; 2015 Feb; 30(2):432-40. PubMed ID: 25492411
[TBL] [Abstract][Full Text] [Related]
3. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles.
Lin MH; Wu FS; Lee RK; Li SH; Lin SY; Hwu YM
Fertil Steril; 2013 Nov; 100(5):1296-302. PubMed ID: 23993928
[TBL] [Abstract][Full Text] [Related]
4. Triggering final oocyte maturation with reduced doses of hCG in IVF/ICSI: a prospective, randomized and controlled study.
Lin H; Wang W; Li Y; Chen X; Yang D; Zhang Q
Eur J Obstet Gynecol Reprod Biol; 2011 Nov; 159(1):143-7. PubMed ID: 21824709
[TBL] [Abstract][Full Text] [Related]
5. Outcome of in vitro fertilization following stimulation with highly purified hMG or recombinant FSH in downregulated women of advanced reproductive age: a prospective, randomized and controlled trial.
Ye H; Huang G; Pei L; Zeng P; Luo X
Gynecol Endocrinol; 2012 Jul; 28(7):540-4. PubMed ID: 22390186
[TBL] [Abstract][Full Text] [Related]
6. Higher birth rate after recombinant hCG triggering compared with urinary-derived hCG in single-blastocyst IVF antagonist cycles: a randomized controlled trial.
Papanikolaou EG; Fatemi H; Camus M; Kyrou D; Polyzos NP; Humaidan P; Tarlatzis B; Devroey P; Tournaye H
Fertil Steril; 2010 Dec; 94(7):2902-4. PubMed ID: 20580358
[TBL] [Abstract][Full Text] [Related]
7. Reducing the trigger dose of recombinant hCG in high-responder patients attending an assisted reproductive technology program: an observational study.
Tiboni GM; Colangelo EC; Ponzano A
Drug Des Devel Ther; 2016; 10():1691-4. PubMed ID: 27274202
[TBL] [Abstract][Full Text] [Related]
8. LH supplementation in mild stimulations cycles without pituitary suppression: a retrospective analysis.
Paragona M; Rossini M; Dattilo M; Stamm J
Gynecol Endocrinol; 2013 Feb; 29(2):101-4. PubMed ID: 23256611
[TBL] [Abstract][Full Text] [Related]
9. A prospective, randomised, investigator-blind, controlled, clinical study on the clinical efficacy and tolerability of two highly purified hMG preparations administered subcutaneously in women undergoing IVF.
Alviggi C; Cognigni GE; Morgante G; Cometti B; Ranieri A; Strina I; Filicori M; De Leo V; De Placido G
Gynecol Endocrinol; 2013 Jul; 29(7):695-9. PubMed ID: 23638621
[TBL] [Abstract][Full Text] [Related]
10. Induction of final follicular maturation and early luteinization in women undergoing ovulation induction for assisted reproduction treatment--recombinant HCG versus urinary HCG. The European Recombinant Human Chorionic Gonadotrophin Study Group.
Hum Reprod; 2000 Jul; 15(7):1446-51. PubMed ID: 10875887
[TBL] [Abstract][Full Text] [Related]
11. Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles.
Barrenetxea G; Agirregoikoa JA; Jiménez MR; de Larruzea AL; Ganzabal T; Carbonero K
Fertil Steril; 2008 Mar; 89(3):546-53. PubMed ID: 17531989
[TBL] [Abstract][Full Text] [Related]
12. Exposure to human chorionic gonadotropin during in vitro maturation does not improve the maturation rate and developmental potential of immature oocytes from patients with polycystic ovary syndrome.
Ge HS; Huang XF; Zhang W; Zhao JZ; Lin JJ; Zhou W
Fertil Steril; 2008 Jan; 89(1):98-103. PubMed ID: 17524398
[TBL] [Abstract][Full Text] [Related]
13. A prospective, randomized, controlled trial comparing three different gonadotropin regimens in oocyte donors: ovarian response, in vitro fertilization outcome, and analysis of cost minimization.
Melo M; Bellver J; Garrido N; Meseguer M; Pellicer A; Remohí J
Fertil Steril; 2010 Aug; 94(3):958-64. PubMed ID: 19931075
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the efficacy and safety of a new recombinant human follicle-stimulating hormone (DA-3801) with follitropin-alpha (Gonal-F) in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology.
Moon SY; Choi YS; Ku SY; Kim SH; Choi YM; Kang IS; Kim CH
J Obstet Gynaecol Res; 2007 Jun; 33(3):305-15. PubMed ID: 17578360
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of highly purified urinary FSH versus recombinant FSH in volunteers undergoing controlled ovarian stimulation for in vitro fertilization: a randomized, multicenter, investigator-blind trial.
Baker VL; Fujimoto VY; Kettel LM; Adamson GD; Hoehler F; Jones CE; Soules MR
Fertil Steril; 2009 Apr; 91(4):1005-11. PubMed ID: 18367182
[TBL] [Abstract][Full Text] [Related]
16. Rescue hCG to treat empty follicle syndrome after the use of a GnRH agonist as oocyte maturation trigger: First report on fresh embryo transfer and clinical pregnancy.
Christopoulos G; Vlismas A; Barsoum-Derias E; El-Shawarby S; Trew G; Lavery S
Hum Fertil (Camb); 2015; 18(4):248-52. PubMed ID: 26400626
[TBL] [Abstract][Full Text] [Related]
17. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study.
Bodri D; Guillén JJ; Galindo A; Mataró D; Pujol A; Coll O
Fertil Steril; 2009 Feb; 91(2):365-71. PubMed ID: 18367175
[TBL] [Abstract][Full Text] [Related]
18. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study.
Humaidan P; Ejdrup Bredkjaer H; Westergaard LG; Yding Andersen C
Fertil Steril; 2010 Feb; 93(3):847-54. PubMed ID: 19200959
[TBL] [Abstract][Full Text] [Related]
19. Gonadotropin-releasing hormone agonist combined with a reduced dose of human chorionic gonadotropin for final oocyte maturation in fresh autologous cycles of in vitro fertilization.
Shapiro BS; Daneshmand ST; Garner FC; Aguirre M; Thomas S
Fertil Steril; 2008 Jul; 90(1):231-3. PubMed ID: 17981269
[TBL] [Abstract][Full Text] [Related]
20. Lag time from ovulation trigger to oocyte aspiration and oocyte maturity in assisted reproductive technology cycles: a retrospective study.
Weiss A; Neril R; Geslevich J; Lavee M; Beck-Fruchter R; Golan J; Shalev E
Fertil Steril; 2014 Aug; 102(2):419-23. PubMed ID: 24880653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
